key: cord-0822094-5ozdhuk0
authors: Buja, L. Maximilian; Wolf, Dwayne; Zhao, Bihong; Akkanti, Bindu; McDonald, Michelle; Lelenwa, Laura; Reilly, Noah; Ottaviani, Giulia; Elghetany, M. Tarek; Trujillo, Daniel Ocazionez; Aisenberg, Gabriel M.; Madjid, Mohammad; Kar, Biswajit
title: EMERGING SPECTRUM OF CARDIOPULMONARY PATHOLOGY OF THE CORONAVIRUS DISEASE 2019 (COVID-19): REPORT OF THREE AUTOPSIES FROM HOUSTON, TEXAS AND REVIEW OF AUTOPSY FINDINGS FROM OTHER UNITED STATES CITIES
date: 2020-05-07
journal: Cardiovasc Pathol
DOI: 10.1016/j.carpath.2020.107233
sha: 0355b0c49d3caf6d131c5174d87a8456d54b9a55
doc_id: 822094
cord_uid: 5ozdhuk0

Abstract This paper collates the pathological findings from initial published autopsy reports on 23 patients with Coronavirus Disease 2019 (COVID-19) from 5 centers in the United States of America, including 3 cases from Houston, Texas. Findings confirm that COVID-19 is a systemic disease with major involvement of the lungs and heart. Acute COVID-19 pneumonia has features of a distinctive acute interstitial pneumonia with: a diffuse alveolar damage (DAD) component, coupled with microvascular involvement with intra- and extra-vascular fibrin deposition and intravascular trapping of neutrophils, and, frequently, with formation of microthombi in arterioles. Major pulmonary thromboemboli with pulmonary infarcts and/or hemorrhage occurred in 5 of the 23 patients. Two of the Houston cases had interstitial pneumonia with DAD pattern. One of the Houston cases had multiple bilateral segmental pulmonary thromboemboli with infarcts and hemorrhages coupled with, in non-hemorrhagic areas, a distinctive interstitial lymphocytic pneumonitis with intra-alveolar fibrin deposits and no hyaline membranes, possibly representing a transition form to acute fibrinous and organizing pneumonia (AFOP). Multifocal acute injury of cardiac myocytes was frequently observed. Lymphocytic myocarditis was reported in 1 case. In addition to major pulmonary pathology, the three Houston cases had evidence of lymphocytic pericarditis, multifocal acute injury of cardiomyocytes without inflammatory cellular infiltrates, depletion of splenic white pulp, focal hepatocellular degeneration and rare glomerular capillary thrombosis. Each had evidence of chronic cardiac disease: hypertensive left ventricular hypertrophy (420 gram heart), dilated cardiomyopathy (1070 gram heart), and hypertrophic cardiomyopathy (670 gram heart). All three subjects were obese (BMIs of 33.8, 51.65 and 35.2 Kg/m2). Overall, the autopsy findings support the concept that the pathogenesis of severe COVID-19 disease involves direct viral-induced injury of multiple organs, including heart and lungs, coupled with the consequences of a procoagulant state with coagulopathy.

A pneumonia of unknown cause was detected in Wuhan, China and was first reported to the World Health Organization (WHO) Country Office in China on 31 December 2019 (1) . The outbreak was identified as a Public Health Emergency of International Concern on 30 January 2020 and was declared a pandemic on March 11, 2020 (2) . On 11 February 2020, WHO announced a name for the new coronavirus disease: COVID-19. The causative virus was identified and designated as SARS-CoV-2. (3, 4) . Clinical reports from China have established that COVID-19 presents as an acute febrile respiratory illness as the dominant feature of a systemic disease involving multiple organ systems (5, 6) .

As the pandemic spread resulting in major morbidity and mortality, it became crystal clear to medically oriented pathologists, forensic pathologists and allied pulmonologists, cardiologists, and critical care physicians that autopsy of deceased victims of the disease was of paramount importance for gaining knowledge of its pathogenesis and pathophysiology. In a letter to the editor of Chest, Xu, Barth and Buja raised a call to action, specifically for as many autopsies to be done as soon as possible to determine the pathologic substrate of this disease (7) . This is based on the well documented importance of the autopsy in establishing the etiology, pathogenesis and response to treatment of emerging diseases (8) .

However, pronouncements by regulatory agencies in the USA have led to confusion, delay and, all too often, suppression of the performance of autopsies at many institutions. Specifically, the Occupational Safety and Health Administration (OSHA) initially issued a contradictory statement with one sentence recommending suspension of post mortem procedures in suspected or confirmed COVID-19 cases and a second sentence indicating that, if deemed necessary and appropriate, strict adherence to basic safety procedures be used while performing such autopsies. In a subsequent statement from OSHA the first sentence was dropped (9) . The Centers for Disease Control (CDC) issued extensive guidelines which included rigorous standards for morgues and autopsy facilities to be under negative pressure with specific standards for venting the air from the rooms (10). There followed a spectrum of administrative responses to the OSHA and CDC directives. But the overall effect has been to create more than necessary impediments for the task before us. Of note and particular relevance for the autopsy situation, Dr. Patricia Harris, President of the American Medical Association, has issued an important statement defending science in a time of fear and uncertainty (11) .

Fortunately for scientific inquiry, several healthcare institutions and medical examiner jurisdictions have persisted in performing autopsies on suspected and confirmed COVID-19

cases. Just as a spectrum of responses has occurred for hospital autopsies, the same applies to medical examiner autopsies. Medical death investigation in the USA is a local function. It varies from state to state and from county to county. There are statewide, county, and regional systems that have substantial differences in their medicolegal jurisdiction. These considerations will determine the extent of COVID-19 autopsies in medical examiner jurisdictions around the country. A great service has been done by Dr. Alex Williamson of the Northwell Health System who has organized an autopsy working group and listserv for the sharing of information (awilliamson@northwell.edu).

Despite the challenges, autopsy studies are being performed and beginning to be reported from several locations around the USA, including Houston, Texas. The purposes of this paper are to collate and summarize the findings from these autopsy studies, including our own three initial cases, to correlate them with emerging clinical information, and to provide thoughts about how this information may help with designing treatment strategies. Correlation with information emerging from China, Europe and other countries also is touched upon.

Liu et al. reported on an 85-year-old Chinese male who died following COVID-19 infection (12) .

The report was limited to gross autopsy findings of heavy lungs with copious amounts of greywhite viscous fluid and unremarkable heart, liver and kidneys. Xu et al. performed postmortem sampling ("biopsies") of tissue from a 50-year-old man who died as a result of COVID-19 infection (13) . Both lungs demonstrated changes consistent with diffuse alveolar damage (DAD), the pathological correlate of acute respiratory distress syndrome (ARDS). The lungs showed interstitial lymphocytic infiltrates and atypical large pneumocytes with cytopathic changes consistent with a viral etiology. A few interstitial mononuclear inflammatory infiltrates were present in the heart and the liver showed moderate microvesicular steatosis.

Tian et al. reported findings on two patients who underwent lung lobectomies for adenocarcinoma and were retrospectively found to have had COVID-19 infection at the time of surgery (14) . On computed tomography (CT) scan, both patients exhibited bilateral ground glass opacities in the peripheral regions of the lungs. Histopathologically, the lungs of both patients exhibited edema, proteinaceous exudate, focal hyperplasia of pneumocytes, patchy inflammatory cellular infiltration, some multinucleated giant cells, and focal intra-alveolar fibrin deposits. Since neither patient had symptoms of pneumonia at the time of surgery, Tian et al.

proposed that the changes likely represent an early phase of the lung pathology of COVID-19 pneumonia (14) .

Two cases have been reported from the Office of the Chief Medical Examiner, Oklahoma City, OK (15) . The decedents were a 77-year-old obese man and a 42-year-old obese man both of whom had positive postmortem nasopharyngeal swab tests for SARS-CoV-2. The first patient had a history of hypertension, splenectomy and 6 days of fever and chills. The second patient was obese, had a history of myotonic dystrophy and developed abdominal pain followed by fever, shortness of breath and cough. Both of the deceased died outside of the hospital, and the autopsies showed evidence of emergency medical intervention, including intubation and chest compressions. Combined weight of the lungs was 2,452 grams for the first case and 1, 191 grams for the second case. On histopathology, the lungs of the first case showed evidence of "DAD in the acute stage characterized by numerous hyaline membranes without evidence of interstitial organization. There was very patchy and sparse interstitial chronic/lymphocytic inflammation, and chronic inflammation and edema in the bronchial mucosa. A few small thrombi were noted within a few small pulmonary artery branches." Focal acute cardiomyocyte damage labeled as ischemic injury was found. Pulmonary pathology of the second case was dominated by acute bronchopneumonia with evidence of aspiration. Neither autopsy revealed viral inclusions, mucus plugging in airways, eosinophils, or myocarditis. The first case had a 402 g heart, marked 2 vessel coronary artery disease, and microscopic evidence of acute ischemic injury. The second case had a 372 gram heart with no evidence of coronary artery disease or myocardial damage. The brains were reported as showing no gross abnormalities.

Four cases have been reported from the Department of Pathology of LSU Health Sciences Center, New Orleans, LA (16) . "The four decedents included male and female patients, ages 44-76. All were African American, and had histories of obesity class 2-3, and hypertension, controlled by medication. Three of the patients had insulin-dependent type II diabetes, two had known chronic kidney disease (stages 2 and 3) and one was taking methotrexate. In all cases the clinical course consisted of approximately three days of mild cough and fever, with sudden respiratory decompensation just prior to arrival in the emergency department. Chest radiographs revealed bilateral ground-glass opacities consistent with ARDS which worsened over the hospital course. The patients were intubated and brought to the Intensive Care Unit.

Whether the patients were placed on ventilators was not specifically stated. All of the patients The parenchyma of each of the lungs was diffusely edematous and firm, consistent with the clinical diagnosis of ARDS. Notably, regions of multifocal dark-colored hemorrhage were prominent. In some cases, small, firm thrombi were present in sections of the peripheral parenchyma on gross examination. Major histological findings were bilateral DAD with multifocal hyaline membranes; a comparatively mild-to-moderate lymphocytic infiltrate, composed of a mixture of CD4+ and CD8+ lymphocytes; and desquamated type 2-pneumocytes with apparent viral cytopathic effect consisting of cytomegaly, and enlarged nuclei with bright, eosinophilic nucleoli. The alveolar capillaries were notably thickened, with surrounding edema, and fibrin thrombi were present within capillaries and small vessels. A notable finding was the presence of CD61+ megakaryocytes, possibly representing resident pulmonary megakaryocytes, with significant nuclear hyperchromasia and atypia. These cells were found within alveolar capillaries, often in association with, and actively producing platelets. The fibrin and platelets present within small vessels also appeared to aggregate inflammatory cells, with entrapment of numerous neutrophils." With the exception of the patient on immunosuppression, no significant neutrophilic infiltrate was found within alveoli or the interstitium to suggest secondary infection.

"Examination of the heart was performed in three cases, with the hearts ranging in size from 430 to 550 grams (normal: 365grams +/-71). The most significant findings were cardiomegaly, and right ventricular dilatation. No case had significant coronary artery stenosis or thrombosis.

Histologically, the sections of myocardium did not show any large or confluent areas of myocyte necrosis. However, there was scattered individual cell myocyte necrosis in each heart examined. Rare interstitial small collections of lymphocytes were seen. There was no significant brisk lymphocytic inflammatory infiltrate consistent with the typical pattern of viral Although no microthrombi were identified on light microscopic examination, electron microscopy revealed strands of precipitated fibrin and entrapped neutrophils within alveolar capillaries as well as larger deposits of fibrin in alveolar spaces (Figures 3-5) . No viral particles were identified in lungs or heart although cytological preservation was suboptimal.

The heart weighed 420 grams and had patent coronary arteries with minimal atherosclerosis.

The thickness of the left ventricular wall was 1.1 centimeters and that of the right ventricular wall was 0.2-0.3 centimeters. The myocardium showed cardiomyocytes with moderately enlarged hyperchromatic nuclei and individual cardiomyocytes with vacuolar degenerative change ( Figure 6 ). There was no evidence of inflammatory infiltrate indicative of myocarditis.

By immunohistochemistry, there were 7-10 or less CD3+ T cells and rare CD68+ macrophages per high power field in the myocardium. Lymphocytic infiltrates composed of CD 3+ T cells with were present in the epicardium with a CD4/CD8 ratio of 2:1. (Figure 6 ). Random sections of the sinoatrial and atrioventricular conduction system showed no abnormalities. The liver showed moderate macrovesicular steatosis without evidence of hepatitis ( Figure 6 ). The kidneys showed evidence of hyaline arteriolosclerosis with glomerulosclerosis. The spleen was enlarged. There was expansion of the red pulp by congestion but also by a lymphoplasmacytic infiltrate ( Figure 7 ). The white pulp was diminished and shrunken with absence of marginal zones. There were scattered immunoblasts near the edge of the small white pulp and scattered into the red pulp. There were no microthrombi or morphological features of vasculitis or a microangiopathic process. There were no macrophages with features of hemophagocytosis, thus no evidence for hemophagocytic lymphohistiocytosis (HLH). The brain was not examined. 

COVID-19 is a viral disease that involves multiple organ systems while usually presenting as an acute febrile respiratory illness (1) (2) (3) (4) (5) (6) (19) (20) (21) (22) (23) (24) (25) (26) (27) (28) (29) (30) (31) . Acute COVID-19 has three distinct phases: early infection, pulmonary and severe hyperinflammation (31) . Prognostic indicators of a more serious and potentially fatal course include older age, lymphopenia, elevated D-dimer level, elevated troponin levels and pre-existing cardiovascular disease, hypertension and diabetes mellitus (19) (20) (21) (22) (23) (24) (25) (26) (27) (28) (29) (30) (31) . The pulmonary and cardiovascular systems are majorly affected (29) (30) (31) .

In spite of obstacles, autopsies are being performed on COVID-19 patients. We have summarized the first reports of small autopsy series, and added three cases from our experience in Houston. The findings are summarized in Tables 1 and 2 . From these initially reported cases, a spectrum of pathology of COVID-19 disease is emerging. The picture will be enhanced as more cases are studied and reported.

Based on clinicopathological correlation from these first 23 autopsy cases, the following observations are made: 1) acute COVID-19 pneumonia, not complicated by prolonged hospitalization and ventilator therapy, is a viral interstitial pneumonia characterized by the early exudative phase of DAD with endothelial and epithelial injury, hyaline membranes, reactive pneumocytes with viral cytopathic effect, and mild combined lymphocytic and histiocytic intra-alveolar inflammation (32-34); 2) after a course of several days, the pulmonary pathology may evolve to a lymphocytic interstitial pneumonitis with intra-alveolar fibrin deposits, which may represent a transition stage to acute fibrinous and organizing pneumonia 

High confidence imaging findings on CT in patients with COVID-19 in the early phase include peripheral and bilateral ground glass opacities sometimes demonstrating a rounded morphology (47) (48) (49) . This pattern of imaging is classically seen with evolving pneumonia explaining the causative pattern of lung injury. With disease progression, more areas of consolidation are seen that can progress to diffuse multifocal airspace disease as seen with DAD and ARDS (46) (47) (48) (49) (50) . Imaging patterns that suggest an alternative diagnosis include a lobar pattern of consolidation, discrete pulmonary micronodules, pleural effusions and lymphadenopathy. Although the bilateral peripheral distribution of opacities is considered to be characteristic of COVID-19, other viral pneumonias, including those produced by certain strains of influenza, also can have a bilateral distribution of radiographic findings (51, 52) .

From the analysis of autopsy findings in fatal COVID-19 cases, the pathological correlate of the imaging findings seen early in the course of COVID-19 is the distinctive interstitial pneumonia with DAD pattern. This COVID-19 interstitial pneumonitis can be accompanied by small vessel thrombi with associated hemorrhage in the lung periphery (16) . The COVID-19 interstitial pneumonitis also may be complicated and masked by multiple pulmonary thomboemboli (Houston Case Two and the two Mt. Sinai cases).

The pathogenesis of COVID-19 pulmonary disease involves binding of SARS-CoV-2 virus to ACE-2 receptors to pneumocytes and endothelial cells leading to development of acute lung injury manifest as DAD (3, 4, 29) . The inflammatory reaction in DAD involves endothelial cell damage, capillary leak, activation of type II pneumocytes, and involvement of polarized pulmonary macrophages (32) (33) (34) (53) (54) (55) (56) (57) . There is also evidence for a role for pulmonary thrombotic microangiopathy in COVID-19 pulmonary disease (16) . The pathophysiology of disease progression likely involves hypoxic pulmonary vasoconstriction (58) .

Also, the possible relationships and merging of the patterns of DAD and organizing pneumonia (OP), also known as bronchiolitis obliterans combined organizing pneumonia (BOOP) and cryptogenic organizing pneumonia (COP), as well as a variant know as acute fibrinous and organizing pneumonia (AFOP), need further study (32) (33) (34) (35) (36) 59) . The dominant feature of AFOP is intra-alveolar fibrin "balls" or aggregates, typically in a patchy distribution. Organizing Mild to moderate troponin elevations, particularly if measured by the high sensitivity troponin assays (hs-Tn), must be interpreted with caution regarding the magnitude of myocardial injury and may not reflect extensive irreversible myocardial injury due to myocardial ischemia or myocardial inflammation. Overt myocarditis, characterized by inflammatory cellular infiltrates with associated cardiomyocyte damage, does occur with COVID-19 infection but is much less common than suggested by overinterpretation of troponin levels (39) (40) (41) (42) (43) . Right heart strain with pulmonary thromboembolism also can be associated with elevated troponin level. However, inflammation of the coronary arteries has not been observed in the Houston COVID-19 autopsy cases. Another manifestation of cardiac involvement in COVID-19 may be stress induced, i.e., Takotsubo cardiomyopathy (69, 70) .

Pre-existing heart disease, diabetes mellitus and obesity clearly predispose to adverse outcome from COVID-19 infection. Of note, the three Houston cases were obese men with evidence of chronic heart disease: hypertension-related left ventricular hypertrophy, dilated cardiomyopathy and hypertrophic cardiomyopathy. The nature of the interactions requires further study. Another phenomenon is that the COVID-19 pandemic is causing patients with acute coronary syndromes (ACS) to delay obtaining treatment or avoid presenting to the hospital for medical attention, with potentially fatal consequences (62) . Patients with cardiac transplants may be at particularly increased risk (71) .

Influenza infection imparts an increased risk for acute myocardial infarction and sudden cardiac death in subsequent months following the acute illness. It is important to determine if COVID-19 infection imparts a similar risk for subsequent cardiovascular events (72, 73) .

COVID-19 infection of organs is initiated by binding of the virus to the ACE-2 receptor on a cell (3, 4, (29) (30) (31) 67) . Thus, the distribution of the ACE-2 receptor in various cell types in different organs determines the involvement of these sites in the progression of COVID-19. The diseases progresses from a pulmonary infection to a systemic disease. In addition to heart and lung, target organ involvement of brain stem, liver and kidneys have been reported (74) (75) (76) (77) . In this report, involvement of the spleen is documented. Even though histological changes in the kidney are relatively mild, many COVID-19 patients are experiencing clinical features of acute renal injury and failure (77) . Endothelial cell infection has been noted in at least two studies (17, 84) . Endothelial cell infection and endotheliitis appears to be an important underlying mechanism linked to vascular dysfunction and thrombotic events in the lung, kidney and possibly the heart and other organs (67, 84) .

Autopsy studies have established that COVID-19 is a systemic disease with major involvement of the cardiovascular and pulmonary systems and with the expected accompaniment of major activation of the inflammatory and immune systems (81, 85) . The autopsy studies also provide evidence that SARS-COV-2 patients have a baseline hypercoagulable state and are at increased risk for pulmonary thrombotic microangiopathy as well as the development of deep vein thromboses and major pulmonary thromboembolism. The autopsy findings support evaluation and management for coagulopathy early in the course of disease and judicious use of prophylactic anticoagulants while hospitalized (86) (87) (88) .

The initial approach to acute therapy for COVID-19 patients with life-threatening respiratory failure has involved administration of supplemental oxygen, artificial ventilation and use of the extracorporeal membrane oxygenator (ECMO) when necessary (89) . Additional approaches and strategies for treatment of COVID-19 patients are actively being pursued, and they are clearly needed (36, (90) (91) (92) . Autopsies on COVID-19 patients need to continue to be performed to further elucidate the natural history of the disease and to guide the development of optimal therapeutic regimens. 

Report of clustering pneumonia of unknown etiology in Wuhan City

Pneumonia of unknown cause -China

A novel coronavirus from patients with pneumonia in China

Genetic Analysis of the Covid-19 Virus and other Pathogens. Golden Helix

Clinical characteristic, treatment and prognosis in 89 cases of COVID-2019] (In Chinese)

Epidemiological and clinical characteristics of 99 cases of 2019 novel corona virus pneumonia in Wuhan, China: A descriptive study

A call for action: the need for autopsies to determine the full extent of organ involvement associated with COVID-19 infection

The importance of the autopsy in Medicine: Perspectives of pathology colleagues

Occupational Safety and Health Administration (OSHA)

Collection and Submission of Postmortem Specimens from Deceased Persons with Known or Suspected COVID-19

Defending science in a time of fear and uncertainty

The autopsy report of the demise patient of 2019 novel corona virus] (In Chinese with English Abstract)

Pathological findings of COVID-19 associated respiratory distress syndrome

Pulmonary pathology of early-phase 2019 novel coronavirus (COVID-19) pneumonia in two patients with lung cancer

COVID-19 autopsies

Vander Heide RS. Pulmonary and cardiac pathology in COVID-19: The first autopsy series from New Orleans

Histopathology and ultrastructural findings of fatal COVID-19 infections

Fatal pulmonary thromboembolism in SARS-CoV-2-infection

Clinical course and outcomes of critically ill patients with SARS-CoV-2 pneumonia in Wuhan, China: a single-centered, retrospective, observational study

Clinical predictors of mortality due to COVID-19 based on an analysis of data of 150 patients from Wuhan, China

Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study

Diabetes is a risk factor for the progression and prognosis of COVID-19

Clinical and immunological features of severe and moderate coronavirus disease 2019

Risk Factors associated with acute respiratory distress syndrome and death in patients with coronavirus disease 2019 pneumonia in Wuhan, China

Clinical and epidemiological features of 36 children with coronavirus disease 2019 (COVID-19) in Zhejiang, China: an observational cohort study

Clinical characteristics of 140 patients infected with SARS-CoV-2 in Wuhan

Presenting Characteristics, Comorbidities, and Outcomes Among 5700 Patients Hospitalized With COVID-19 in the New York City Area

Hematologic, biochemical and immune biomarker abnormalities associated with severe illness and mortality in coronavirus disease 2019 (COVID-19): a meta-analysis

2020;/j/cclm.ahead-of-print

Pathopysiological characteristics and therapeutic approaches for pulmonary injury and cardiovascular complications of Coronavirus Disease

Potential Effects of Coronaviruses on the Cardiovascular System: A Review

COVID-19 and the Heart

Acute lung injury

Diffuse alveolar damage--the role of oxygen, shock, and related factors. A review

Pulmonary pathology of acute respiratory distress syndrome

Acute fibrinous and organizing pneumonia: a histological pattern of lung injury and possible variant of diffuse alveolar damage

Time to consider histologic pattern of lung injury to treat critically ill patients with COVID-19 infection

Pulmonary pathology of severe acute respiratory syndrome in Toronto

Pathology and pathogenesis of severe acute respiratory syndrome

Clinicopathological complexity in the application of the universal definition of myocardial infarction

Clinicopathological manifestations of myocarditis in a heart failure population

High-sensitivity troponin and the Application of risk stratification thresholds in patients with suspected acute coronary syndrome

Cardiac troponin I in patients with coronavirus disease 2019 (COVID-19): Evidence from a meta-analysis. Prog Cardiovasc Dis

High-Sensitivity Cardiac Troponin Can Be An Ally in the Fight Against COVID-19

Higher co-infection rates in COVID19

Is COVID-19 receiving ADE from other coronaviruses?

It is too soon to attribute ADE to COVID-19

Performance of radiologists in differentiating COVID-19 from viral pneumonia on chest CT

CT Imaging Features of 2019 Novel Coronavirus

Radiological Society of North America Expert Consensus Statement on reporting chest CT findings related to COVID-19. Endorsed by the Society of Thoracic Radiology, the American Academy of Radiology, and the RSNA. Radiology: CT Imaging

Pathology-radiology correlation of common and uncommon computed tomographic patterns of organizing pneumonia

Viral pneumonia

Clinical and Radiographic Comparison of Influenza Virus-associated Pneumonia among Three Viral Subtypes

ARDS and diffuse alveolar damage: a pathologist's perspective

Acute respiratory distress syndrome and diffuse alveolar damage. New insights on a complex relationship

NETs promote ALI/ARDS inflammation by regulating alveolar macrophage polarization

Alveolar Macrophage Transcriptional Programs Are Associated with Outcomes in Acute Respiratory Distress Syndrome

Transcriptomic characteristics of bronchoalveolar lavage fluid and peripheral blood mononuclear cells in COVID-19 patients

Hypoxic pulmonary vasoconstriction: physiology and anesthetic implications

Chronic diffuse lung diseases

Cardiovascular disease and COVID-19

Cardiovascular Implications of Fatal Outcomes of Patients With Coronavirus Disease 2019 (COVID-19)

Impact of Coronavirus Disease 2019 (COVID-19) Outbreak on ST-Segment-Elevation Myocardial Infarction Care in Hong Kong, China

Chinese with English Abstract)

Cardiac involvement in a patient with coronavirus disease 2019 (COVID-19)

Myocardial localization of coronavirus in COVID-19 cardiogenic shock

Ultrastructure of human nasal epithelium during an episode of coronavirus infection

The ACE2 expression in human heart indicates new potential mechanism of heart injury among patients infected with SARS-CoV-2

Systemic infections cause exaggerated local inflammation in atherosclerotic coronary arteries: clues to the triggering effect of acute infections on acute coronary syndromes

Stress cardiomyopathy: yet another type of neurocardiogenic injury: 'stress cardiomyopathy'

Takotsubo Cardiomyopathy presenting with different morphological patterns in the same patient: a case report and review of the literature

COVID-19: Yet another coronavirus challenge in transplantation

Outcomes of acute myocardial infarction in patients with influenza and other viral respiratory infections

Influenza and cardiovascular disease: is there a causal relationship?

The neuroinvasive potential of SARS-CoV2 may play a role in the respiratory failure of COVID-19 patients

Liver injury during highly pathogenic human coronavirus infections

Renal histopathological analysis of 26 postmortem findings of patients with COVID-19 in China

An overlooked, possibly fatal coronavirus crisis: a dire need for kidney dialysis

The nucleocapsid protein of SARS-CoV induces transcription of hfgl2 prothrombinase gene dependent on C/EBP alpha

TTP-like syndrome: novel concept and molecular pathogenesis of endotheliopathy-associated vascular microthrombotic disease

Sepsis and septic shock: endothelial molecular pathogenesis associated with vascular microthrombotic disease

COVID-19, cytokines and immunosuppression: what can we learn from severe acute respiratory syndrome?

Current Pathological and Laboratory Considerations in the Diagnosis of Disseminated Intravascular Coagulation

Systemic inflammatory response syndromes in the era of interventional cardiology

Endothelial cell infection and endotheliitis in COVID-19

Insights from immuno-oncology: The Society for Immunotherapy of Cancer statement on access to IL-6-targeting therapies for COVID-19

COVID-19 and Thrombotic or Thromboembolic Disease: Implications for Prevention, Antithrombotic Therapy, and Follow-up. J Am Col Cardiol

Anticoagulant treatment is associated with decreased mortality in severe coronavirus disease 2019 patients with coagulopathy

The versatile heparin in COVID-19

COVID-19, ECMO, and lymphopenia: a word of caution

Hiding in Plain Sight: an Approach to Treating Patients with Severe COVID-19 Infection

COVID-19 and Angiotensin-Converting Enzyme Inhibitors and Angiotensin Receptor Blockers: What Is the Evidence?

Potential harmful effects of discontinuing ACE-inhibitors and ARBs in COVID-19 patients